Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway

The Original Article was published on 22 August 2020

Correction to: Cell Death & Disease

https://doi.org/10.1038/s41419-020-02912-0 published online 22 August 2020

The original version of this Article contained errors in the author affiliations.

Zhida Chen was incorrectly associated with Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, China. Haonan Li, Qiao Qiao and Qing Zhu were incorrectly associated with Department of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

This has now been corrected in both the PDF and HTML versions of the Article.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Qing Zhu or Lei Wang.

Additional information

Edited by F. Pentimalli

The original article can be found online at https://doi.org/10.1038/s41419-020-02912-0.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, Z., Wu, C., Liu, Y. et al. Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway. Cell Death Dis 11, 905 (2020). https://doi.org/10.1038/s41419-020-02933-9

Download citation

Search